The key component in CorMedix’s flagship investigational drug product, DefenCath™, is taurolidine, a synthetic broad-spectrum antimicrobial and antifungal with anti-inflammatory and potential anti-tumor activities.
Taurolidine is derived from the natural amino acid taurine and its antimicrobial activity is directed at the bacterial cell surface.
Taurolidine also inhibits expression of key inflammatory molecules tumor necrosis factor – alpha (TNF-α) and interleukin 1b. Although the mechanisms underlying its anti-tumor activity are not fully elucidated, taurolidine has been shown to inhibit new blood vessel formation within tumors and enhance cancer cell death through apoptosis, as well as reduce tumor cell adhesion.
CorMedix is conducting research to explore additional uses for taurolidine, including oncology and medical devices. The Company would look to establish strategic partnerships to advance these products once proof of concept is achieved.
- Synergy with vincristine
- Increased Efficacy
- Lower Toxicity
- Synergy with vincristine
- Increased Efficacy
- Lower Toxicity
Protects surgical sites from infection
- Burns and wounds
- Diabetic foot ulcers
- Biofilm prevention
- Hernia Repair
- Wound Management
- Burns
